

# Receipt

1

peutic Compounds

~~~~~

Group Art Unit: 1614

Attorney  
Docket: **24214**

Attorney  
Docket: **24214**

**AMENDED REQUEST FOR CORRECTED FILING RECEIPT**

This Amended Request For Corrected Filing Receipt is in response to the Response to Request for Corrected Filing Receipt dated September 9, 2004, a copy of which is attached.

Attached is a copy of the official filing receipt received from the United States Patent and Trademark Office in the above application. Issuance of a corrected filing receipt to correct an error of the USPTO is respectfully requested.

Please amend the “Domestic Priority data as claimed by applicant:

“This application claims priority from 09/495,723 02/01/2000 which is a divisional of 08/486,127 06/07/1995, Pat. No. 6,020,323 which is a continuation of 08/436,330 05/10/1995, Pat. No. 5,861,382 which claims priority from PCT/US93/10868 11/09/1993 which is a continuation in part of 07/096,739 07/23/1993, which is a continuation in part of 07/974,750 11/10/1992 which is a continuation in part of 07/878,188 05/01/1992”


A copy of the first paragraph of the specification is attached hereto.

Respectfully submitted,

  
Sol Sheinbein

Registration No. 25,457

Date: October 20, 2004




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

| APPLICATION NUMBER | FILING DATE | GRP ART UNIT | FIL FEE REC'D | ATTY. DOCKET NO | DRAWINGS | TOT CLAIMS | IND CLAIMS |
|--------------------|-------------|--------------|---------------|-----------------|----------|------------|------------|
| 10/002,145         | 12/05/2001  | 1614         | 469           | B12/31          | 11       | 31         | 2          |

CONFIRMATION NO. 4185

## FILING RECEIPT



\*OC000000007292560\*

C/O THE POLKINGHORNS  
9003 FLORIN WAY  
UPPER MARLBORO, MD 20772

Date Mailed: 01/10/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Liora Cahalon, Givataim, ISRAEL;  
Irun R. Cohen, Rehovot, ISRAEL;

Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted 01/10/2002

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No


\*\* SMALL ENTITY \*\*

## Title

Novel anti-cancer therapeutic compounds

Preliminary Class

514



UNITED STATES PATENT AND TRADEMARK OFFICE

24214

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

| APPLICATION NUMBER | FILING OR 371(c) DATE | FIRST NAMED APPLICANT | ATTY. DOCKET NO./TITLE |
|--------------------|-----------------------|-----------------------|------------------------|
| 10/002,145         | 12/05/2001            | Liora Cahalon         | B12/31                 |

C/O THE POLKINGHORNS  
 9003 FLORIN WAY  
 UPPER MARLBORO, MD 20772

CONFIRMATION NO. 4185



\*OC000000013766722\*

Date Mailed: 09/09/2004


## RESPONSE TO REQUEST FOR CORRECTED FILING RECEIPT

### Domestic Continuity and Foreign Priority

In response to your request for a corrected Filing Receipt, the Office is unable to comply with the request because:

- ☐ The priority or continuity claim has not been entered because it was not filed during the required time period. Applicant may wish to consider filing a petition to accept an unintentionally delayed claim for priority. See 37 CFR 1.55 or 1.78.
- ☒ Continuity claimed under 35 U.S.C. § 120 cannot be added to the Filing Receipt without the applicant supplying the relationship (continuation, divisional, or continuation-in-part) in an Application Data Sheet or amendment to the first page of the specification.
- ☐ A claim for priority cannot be made based on an application filed after the application making the claim.
- ☐ Domestic benefit and foreign priority claims will not be captured in a provisional application. A provisional application is not entitled to a right of priority or to the benefit of an earlier filing date of any other application. See 35 U.S.C. § 111(b)(7) and 37 CFR 1.53(c)(4).
- ☐ A domestic continuity claim cannot be made to a foreign application and the filing receipt will only list the foreign country, application number, and filing date.
- ☐ Foreign priority will appear on the Filing Receipt in the following order: **Country, Application number, Filing date.**
- ☐ This application is the result of a conversion from a provisional application. Priority based on such application cannot be made since it no longer exists as a provisional application.
- ☐ The application(s) to which priority is claimed were filed over a year prior to the filing date of this application. Therefore, the referenced application(s) cannot be claimed as domestic or foreign priority.

- ☐ To change the benefit claim of a U.S. prior-filed application, applicant must amend the first sentence of of the specification (if the benefit claim is referenced in the specification), or provide a supplemental application data sheet (ADS) (if the benefit claim was submitted in an ADS), with the desired benefit claim. Note that once a benefit claim is deleted, applicant will not be able to claim such prior-filed application again, if the above-identified application was filed on or after November 29, 2000.
- ☐ To change a foreign priority claim, applicant must submit a supplemental oath or declaration (if the priority claim is referenced in the oath or declaration), or a supplemental application data sheet (ADS) (if the priority claim was submitted in an ADS), with the desired priority claim. If a supplemental ADS is submitted, any deletions should be shown with strikeouts. Note that once a priority claim is deleted, applicant will not be able to claim such foreign application again, if the above-identified application was filed on or after November 29, 2000.



Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



## APPLICATION FOR PATENT

INVENTORS: Liora Cahalon, Irun R. Cohen, Ofer Lider and Raanan  
Margalit

TITLE: NOVEL ANTI-CANCER THERAPEUTIC COMPOUNDS

5

This Application claims priority from US Patent No. 6,020,323, filed on June 7,  
1995, as US Patent Application No. 08/486,127 and issued on February 1, 2000,  
which is a continuation of US Patent Application No. 08/436,330, filed on June 29,  
1995, now US Patent No. 5,861,382, issued on January 19, 1999, which claims  
10 priority from PCT Application No. PCT/US93/10868, filed on November 9, 1993,  
and which is a continuation in part of US Patent Application No. 07/096,739, filed  
on July 23, 1993, abandoned, which is a continuation in part of US Patent  
Application No. 07/974,750, filed on November 10, 1992, abandoned, which is a  
continuation in part of US Patent Application No. 07/878,188, filed on May 1,  
15 1992, abandoned; and US Patent Application No. 09/495,723, filed on February 1,  
2000, currently pending; all of which are owned in common with the present  
application, and all of which are hereby incorporated by reference as if fully set  
forth herein.

### 20 FIELD OF THE INVENTION

The present invention is of therapeutic compounds for cancer, and in  
particular, of therapeutic compounds which block the ability of cytokines and  
chemokines to promote metastasis of malignant cells, and which are heparin and